Louise A Brinton1. 1. Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. brinton@nih.gov
Abstract
AIM: To evaluate male breast cancer (MBC) risk among patients with Klinefelter syndrome (KS) and relate this to possible biological explanations. METHODS: A literature review was conducted to identify case series and epidemiologic studies that have evaluated MBC risk among patients with KS. RESULTS: Case reports without expected values have often led to false impressions of risk. Problems include that a diagnosis of cancer can prompt a karyotypic evaluation and that many cases of KS are unrecognized, resulting in incomplete denominators. Few carefully conducted epidemiologic studies have been undertaken given that both KS and MBC are rare events. The largest study found 19.2- and 57.8-fold increases in incidence and mortality, respectively, with particularly high risks among 47,XXY mosaics. These risks were still approximately 70% lower than among females, contradicting case reports that patients with KS have breast cancer rates similar to females. Altered hormone levels (especially the ratio of oestrogens to androgens), administration of exogenous androgens, gynaecomastia and genetic factors have been offered as possible explanations for the high risks. CONCLUSIONS: Additional well-designed epidemiologic studies are needed to clarify which patients with KS are at a high risk of developing MBC and to distinguish between possible predisposing factors, including altered endogenous hormones.
AIM: To evaluate male breast cancer (MBC) risk among patients with Klinefelter syndrome (KS) and relate this to possible biological explanations. METHODS: A literature review was conducted to identify case series and epidemiologic studies that have evaluated MBC risk among patients with KS. RESULTS: Case reports without expected values have often led to false impressions of risk. Problems include that a diagnosis of cancer can prompt a karyotypic evaluation and that many cases of KS are unrecognized, resulting in incomplete denominators. Few carefully conducted epidemiologic studies have been undertaken given that both KS and MBC are rare events. The largest study found 19.2- and 57.8-fold increases in incidence and mortality, respectively, with particularly high risks among 47,XXY mosaics. These risks were still approximately 70% lower than among females, contradicting case reports that patients with KS have breast cancer rates similar to females. Altered hormone levels (especially the ratio of oestrogens to androgens), administration of exogenous androgens, gynaecomastia and genetic factors have been offered as possible explanations for the high risks. CONCLUSIONS: Additional well-designed epidemiologic studies are needed to clarify which patients with KS are at a high risk of developing MBC and to distinguish between possible predisposing factors, including altered endogenous hormones.
Authors: A H Wu; A S Whittemore; L N Kolonel; E M John; R P Gallagher; D W West; J Hankin; C Z Teh; D M Dreon; R S Paffenbarger Journal: Cancer Epidemiol Biomarkers Prev Date: 1995 Oct-Nov Impact factor: 4.254
Authors: Anthony J Swerdlow; Minouk J Schoemaker; Craig D Higgins; Alan F Wright; Patricia A Jacobs Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Samuel F Gilbert; Amr S Soliman; Mehdi Karkouri; Meaghen Quinlan-Davidson; Ashley Strahley; Mohab Eissa; Subhojit Dey; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Noureddine Benjaafar; Kathy Toy; Sofia D Merajver Journal: Breast Dis Date: 2011
Authors: Louise A Brinton; Tim J Key; Laurence N Kolonel; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Shannon N Wood; Roni T Falk; Dominick Parisi; Chantal Guillemette; Patrick Caron; Véronique Turcotte; Laurel A Habel; Claudine J Isaacs; Elio Riboli; Elisabete Weiderpass; Michael B Cook Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Samuel F Gilbert; Amr S Soliman; Maria Iniesta; Mohab Eissa; Ahmed Hablas; Ibrahim A Seifeldin; Ashley Strahley; Mousumi Banerjee; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2011-04-20 Impact factor: 4.872
Authors: Andrea Sansone; Francesco Romanelli; Massimiliano Sansone; Andrea Lenzi; Luigi Di Luigi Journal: Endocrine Date: 2016-05-04 Impact factor: 3.633
Authors: Arthur P Arnold; Karen Reue; Mansoureh Eghbali; Eric Vilain; Xuqi Chen; Negar Ghahramani; Yuichiro Itoh; Jingyuan Li; Jenny C Link; Tuck Ngun; Shayna M Williams-Burris Journal: Philos Trans R Soc Lond B Biol Sci Date: 2016-02-01 Impact factor: 6.237
Authors: Stephanie M Fullerton; Wendy A Wolf; Kyle B Brothers; Ellen Wright Clayton; Dana C Crawford; Joshua C Denny; Philip Greenland; Barbara A Koenig; Kathleen A Leppig; Noralane M Lindor; Catherine A McCarty; Amy L McGuire; Eugenia R McPeek Hinz; Daniel B Mirel; Erin M Ramos; Marylyn D Ritchie; Maureen E Smith; Carol J Waudby; Wylie Burke; Gail P Jarvik Journal: Genet Med Date: 2012-02-23 Impact factor: 8.822